Ze'an Biopharmaceutical
泽安生物医药
Ze'an Biopharmaceutical (LTZ Therapeutics) is a clinical-stage biotechnology company founded in 2022 by CEO Dr. Robert Li (Jinze Li), developing first-in-class immunotherapies based on its proprietary U-MCE™ (Universal Myeloid Cell Engager) platform . The platform harnesses myeloid cells as effector cells to target cancer and autoimmune diseases, with lead candidate LTZ-301 in Phase I studies in the US and LTZ-232 advancing toward IND .
The company has raised roughly $130 million to date, including a $40 million Series A+ in April 2025 led by Wanwu Venture Capital with participation from BlueRun Ventures, 5Y Capital, and Hillhouse, followed by a $38 million round in May 2026 led by GL Ventures . Its platform has drawn two major pharma partnerships within four months: a July 2025 autoimmune-focused collaboration with Eli Lilly involving an equity stake and tiered royalties, and a November 2025 oncology deal with GSK for up to four first-in-class candidates, carrying a $50 million upfront plus milestones .
AI-generated — may contain errors, please verify.
Coverage
BlueRun Ventures Portfolio Company NeoImmuneTech Completes $38 Million Financing to Advance First-in-Class "Myeloid Cell Engager" Immunotherapy Pipeline | BlueRun Family
From Technical Platform Validation to Clinical Value
In the AI Era, There Are Only Builders — No Seats on the Sidelines | Quarterly
Let's go.
$50 Million Upfront Payment! Zeon Secures Another Partnership with Global Pharma Giant | BlueRun Ventures Family Headlines
Ze'an Partners with Another Global Pharma Giant
They Talk, We Create | Quarterly
The evening breeze of a summer night is the sound of the future rushing in.
Partnering with Eli Lilly and Company! Zai Lab's Globally First-in-Class "Myeloid Cell Engager" Platform Opens New Frontiers in Autoimmune Disease Treatment | BlueRun Ventures Family Headlines
Zean Bioscience Charts a New Course for Autoimmune Disease Treatment
Planting Spring in the Wind | Quarterly
On the Move
Zean completes $40 million Series A+ round to accelerate development of myeloid cell engager pipeline | BlueRun Ventures Family
Focusing on unmet clinical needs in major disease areas such as cancer and autoimmune diseases.
